How Does Mitral Valve Stenosis Cause Atrial Fibrillation?
At a Glance
Mitral valve stenosis raises pressure in the left atrium, stretching it and disrupting heart signals, which can cause atrial fibrillation. Opening the valve may improve blood flow, but AF can persist or return, so heart-rate treatment and blood thinners remain important for stroke prevention.
In this answer
5 sections
When you have significant or severe mitral valve stenosis, the narrowed valve limits blood flow from your upper left heart chamber (the left atrium) to the lower chamber (the left ventricle). To push blood through this narrowing, pressure inside the left atrium increases [1]. Over time, this chronic high pressure forces the left atrium to stretch and physically change—a process called remodeling [2]. This stretching can damage the heart muscle fibers and create scar tissue (fibrosis), which disrupts the heart’s normal electrical pathways [2]. As the electrical signals become chaotic, they trigger atrial fibrillation (AF), an irregular heartbeat that can be fast, slow, or normal-rate [2][3]. In populations with rheumatic mitral stenosis (caused by past rheumatic fever), AF is very common, affecting an estimated 40% to 75% of people depending on age and disease severity [4].
Why Atrial Fibrillation Affects Your Symptoms
When your heart is in its normal rhythm (called sinus rhythm), the left atrium squeezes (contracts) to help push the last bit of blood through the mitral valve [5]. When atrial fibrillation occurs, the upper chambers quiver instead of squeezing, meaning you lose this helpful “kick” of blood [6].
Furthermore, AF often causes a rapid heart rate. Because the heart is beating fast, there is less time for blood to cross the narrowed valve between beats. This backup of blood into the lungs is why developing AF can cause a sudden, dramatic worsening of mitral stenosis symptoms, such as shortness of breath or fatigue [3][6]. Note that AF can also be “silent,” meaning you might not feel it, and it is confirmed with an electrocardiogram (ECG), not just by symptoms alone.
Emergency Warning: If you experience sudden, severe shortness of breath at rest, fainting, chest pain, coughing up pink/frothy sputum, a sustained very rapid heartbeat with dizziness, or signs of a stroke (like facial droop, arm weakness, or trouble speaking), call emergency services immediately. Never change your medication doses without medical advice.
Controlling the Heart Rate
If your heart rate is too fast, the immediate goal is often rate control [7].
- Beta-blockers or calcium-channel blockers (like diltiazem or verapamil): These are often used to slow the heart down [7]. However, they are prescribed only when appropriate for your specific blood pressure and heart function, and they may be unsafe if you have low blood pressure or certain types of heart failure [8].
- Digoxin: This may be added or used instead, but it has limitations and requires careful monitoring [7][3].
There is no universal heart rate rule. A common initial target for a resting heart rate is below 110 beats per minute, but your doctor will individualize your target based on your symptoms, age, and medication side effects [7].
Will Treating the Valve Restore a Normal Rhythm?
Patients often wonder if fixing the narrowed valve will automatically fix the electrical problem.
If you have severe, symptomatic mitral stenosis, treating the valve is a critical step [9]. For many, this involves a procedure called percutaneous mitral balloon commissurotomy (PMBC), where a balloon is used to open the valve [9][3]. However, PMBC is only an option if your echocardiogram shows suitable valve anatomy (for example, if there is no heavy calcification, no major valve leakage, and no blood clot in the atrium) [10][11]. If PMBC is not suitable, surgery may be necessary.
Opening the valve successfully lowers the pressure inside the left atrium, which can allow the chamber to shrink slightly [12]. However, because the physical stretching of the atrium may be permanent, atrial fibrillation has a high risk of persisting or returning even after valve treatment [3][13]. A larger left atrium before treatment is a strong predictor that AF will continue [13].
Cardioversion: Attempting to Reset the Rhythm
Sometimes, doctors attempt a cardioversion—delivering a synchronized electrical shock to the heart to “reset” it back to a normal sinus rhythm [3].
- Timing: Cardioversion is typically considered after the mitral valve has been successfully treated. Restoring rhythm while the valve is still severely narrowed is usually unsuccessful [3][14]. (In a true emergency where a rapid heart rate is causing shock or severe instability, doctors may perform urgent cardioversion immediately [15]).
- Checking for Clots: Before a planned cardioversion, doctors must ensure there are no blood clots in your heart. They do this either by ensuring you have taken therapeutic blood thinners consistently for at least 3 weeks, OR by performing a Transesophageal Echocardiogram (TEE—an ultrasound probe passed down the throat to look closely at the atrium) [16]. TEE is highly recommended if blood thinner adherence is uncertain. If a clot is found, cardioversion is postponed [16].
- Ongoing Protection: Having a TEE that shows no clot does not mean you can stop blood thinners. Anticoagulation must be continued during and for at least 4 weeks after the procedure [3].
Preventing Stroke: Blood Thinners
Atrial fibrillation dramatically increases the risk of blood clots and stroke [17]. For patients with moderate-to-severe rheumatic mitral stenosis and AF, strict guidelines govern the use of blood thinners (anticoagulants), depending on a safety check of your bleeding risk:
- Vitamin K Antagonists (VKAs) are recommended: The standard recommendation is a VKA, such as warfarin [18]. Unlike with other types of AF, newer blood thinners (called DOACs, like rivaroxaban) are not recommended for moderate-to-severe rheumatic mitral stenosis [19]. A large trial (INVICTUS) proved that warfarin is superior at preventing cardiovascular events in this group [19][18].
- Universal risk: In moderate-to-severe rheumatic mitral stenosis, blood thinners are strongly recommended regardless of your age or other standard stroke risk factors (often calculated by doctors as a “CHA₂DS₂-VASc score”) [3].
- Monitoring your INR: Warfarin requires regular blood tests called an INR to ensure the medication is working safely. Your doctor will set your target INR range (often 2.0–3.0, but it may be different if you have a mechanical valve) [20].
- Long-term commitment: Never stop your blood thinner without consulting your doctor. Even if cardioversion or valve treatment restores a normal sinus rhythm, your doctor will likely recommend continuing the blood thinner long-term if you have a history of AF with significant mitral stenosis, an enlarged left atrium, or prior clots [3]. For patients with a mechanical replacement valve, lifelong VKA therapy is always required [21].
Common questions in this guide
What is the link between mitral valve stenosis and atrial fibrillation?
Why can atrial fibrillation suddenly worsen symptoms from mitral stenosis?
Does fixing the mitral valve make atrial fibrillation go away?
Which blood thinner is used when atrial fibrillation occurs with rheumatic mitral stenosis?
What needs to happen before cardioversion for mitral stenosis-related AF?
What symptoms mean I should seek emergency help?
Related questions
Show more
Get notified when new evidence is published on mitral valve stenosis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (21)
- 1
Mitral valve stenosis in the current era: a changing landscape.
Giannini C, Mazzola M, Pugliese NR, Petronio AS
Journal of cardiovascular medicine (Hagerstown, Md.) 2022; (23(11)):701-709 doi:10.2459/JCM.0000000000001384.
PMID: 36219149 - 2
Giant Left Atrial Thrombus Despite Anticoagulation with Apixaban in a Patient with Mitral Stenosis and Atrial Fibrillation.
Turek Ł, Sadowski M, Janion-Sadowska A, et al.
The American journal of case reports 2021; (22()):e933162 doi:10.12659/AJCR.933162.
PMID: 34561412 - 3
Management of atrial fibrillation in patients with rheumatic mitral stenosis.
Iung B, Leenhardt A, Extramiana F
Heart (British Cardiac Society) 2018; (104(13)):1062-1068 doi:10.1136/heartjnl-2017-311425.
PMID: 29453328 - 4
Anticoagulation in Atrial Fibrillation Associated with Mitral Stenosis.
da Silva RMFL
Cardiovascular & hematological agents in medicinal chemistry 2022; (20(3)):172-174 doi:10.2174/1871525720666220321120944.
PMID: 35319395 - 5
Comparative assessment of left and right atrial deformation using 2D and 3D speckle-tracking echocardiography in healthy individuals and rheumatic mitral stenosis patients with/without atrial fibrillation.
Seçkin Göbüt Ö, Ünlü S, Taçoy Aydoğdu G
Postgraduate medicine 2025; (137(3-4)):309-317 doi:10.1080/00325481.2025.2478819.
PMID: 40091283 - 6
A Case of Success: Guidelines-Based Treatment to Control Atrial Fibrillation-Induced Cardiomyopathy-Atrioventricular Node Ablation and Cardiac Resynchronization Therapy to the Rescue.
Jonaitienė N, Ramantauskaitė G, Laukaitienė J
Reports (MDPI) 2025; (8(3)) doi:10.3390/reports8030150.
PMID: 40843892 - 7
Rate control versus rhythm control in atrial fibrillation: lessons learned from clinical trials of atrial fibrillation.
Waldo AL
Progress in cardiovascular diseases 2015; (58(2)):168-76.
PMID: 26260611 - 8
The controversies in the clinical management of β-blockers in acute heart failure induced by rapid atrial fibrillation: A narrative review.
Zhu W, Xu J, Zhang L
American heart journal plus : cardiology research and practice 2025; (60()):100655 doi:10.1016/j.ahjo.2025.100655.
PMID: 41282304 - 9
Rheumatic Mitral Valve Stenosis: Diagnosis and Treatment Options.
Wunderlich NC, Dalvi B, Ho SY, et al.
Current cardiology reports 2019; (21(3)):14 doi:10.1007/s11886-019-1099-7.
PMID: 30815750 - 10
Characteristics and immediate outcomes of patients who underwent percutaneous balloon mitral valvuloplasty at the Jakaya Kikwete Cardiac Institute, Tanzania.
Mutagaywa RK, Cramer MJ, Chillo P, et al.
Cardiovascular journal of Africa 2024; (35(1)):16-26 doi:10.5830/CVJA-2022-068.
PMID: 36745007 - 11
Echocardiography Assessment of Rheumatic Heart Disease: Implications for Percutaneous Balloon Mitral Valvuloplasty.
Mohamed Ali A, Packer EJS, Omdal TR, et al.
Current problems in cardiology 2023; (48(12)):102021 doi:10.1016/j.cpcardiol.2023.102021.
PMID: 37544629 - 12
Left Atrium and Mitral Valve Hemodynamics in Patients With Mitral Stenosis Pre and Post-Percutaneous Balloon Mitral Valvuloplasty: A Systematic Review and Meta-Analysis.
Zaied MA, Shahzaib M, Mukhlis M, et al.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2026; (107(6)):2078-2097 doi:10.1002/ccd.70558.
PMID: 41891287 - 13
Incidence and predictors of de novo late-onset persistent atrial fibrillation in postoperative rheumatic heart disease patients (LOAF-RHD study).
Sharma G, Ghati N, Doshi S, et al.
Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing 2022; (64(3)):621-628 doi:10.1007/s10840-021-01085-w.
PMID: 34748162 - 14
Evaluation of early direct current cardioversion for maintenance of sinus rhythm in rheumatic atrial fibrillation following successful balloon mitral valvotomy.
Sharma G, Anantha Krishnan R, Bohra V, et al.
Indian heart journal 2016; (68(4)):486-92.
PMID: 27543470 - 15
A giant and double-walled left atrial ball thrombus complicating a mitral stenosis: case report-a truck tire into the heart.
Selimi A, Ianni U, Molisana M, Parato VM
European heart journal. Case reports 2022; (6(11)):ytac443 doi:10.1093/ehjcr/ytac443.
PMID: 36466129 - 16
Left Atrial Thrombus in Rheumatic Mitral Stenosis: A Case of Therapeutic International Normalized Ratio Failure.
Sabri MS, Weber C, Belkadi Y, et al.
JACC. Case reports 2025; (30(26)):104884 doi:10.1016/j.jaccas.2025.104884.
PMID: 40912841 - 17
Effects of percutaneous balloon mitral valvuloplasty in patients with mitral stenosis and atrial fibrillation: a systematic review and meta-analysis.
Liu B, Wang Y, Liu Y, et al.
Acta cardiologica 2022; (77(10)):890-899 doi:10.1080/00015385.2021.1989837.
PMID: 34866553 - 18
Anticoagulation for rheumatic mitral stenosis, INVICTUS in perspective.
Verma R, Latter DA
Current opinion in cardiology 2023; (38(2)):55-60 doi:10.1097/HCO.0000000000001013.
PMID: 36718615 - 19
Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Moderate to Severe Mitral Stenosis: A Systematic Review.
Al Rawahi MN, Al-Maqbali JS, Al Noumani J, et al.
Cureus 2023; (15(1)):e33222 doi:10.7759/cureus.33222.
PMID: 36741597 - 20
Can Direct Oral Anticoagulants Be Used for Stroke Prevention Among Patients with Valvular Atrial Fibrillation?
Anderson SL, Marrs JC
Current cardiology reports 2019; (21(10)):118 doi:10.1007/s11886-019-1199-4.
PMID: 31473836 - 21
Direct oral anticoagulant use in nonvalvular atrial fibrillation with valvular heart disease: a systematic review.
Owens RE, Kabra R, Oliphant CS
Clinical cardiology 2017; (40(6)):407-412 doi:10.1002/clc.22659.
PMID: 28004413
This page is for informational purposes only and does not constitute medical advice. Your cardiologist should guide decisions about heart-rate medicines, valve procedures, cardioversion, and blood thinners.